MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on Thursday, September 12, 2024..

新泽西州马瓦赫（商业新闻短讯）--KORU Medical Systems（纳斯达克：KRMD）（“KORU Medical”或“公司”）是一家领先的医疗技术公司，专注于创新性和以患者为中心的大容量皮下输液的开发，制造和商业化，今天宣布该公司将参加2024年9月12日星期四在纽约举行的第八届年度Lake Street Best Ideas成长大会的投资者会议。。

About KORU Medical Systems

关于KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™.

KORU Medical Systems开发、制造和商业化创新的以患者为中心的大容量皮下输液解决方案，以提高世界各地患者的生活质量。FREEDOM注射器输液系统（“FREEDOM系统”）目前包括FREEDOM60®和FreedomEdge®注射器输液驱动器、Precision Flow Rate Tubbing™和HIgH-Flo皮下安全针头套件™。

The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories.

Freedom系统于1994年首次获得FDA批准，用于患者在家中自我管理和/或由医疗保健专业人员在门诊输液中心分娩。通过其新型疗法业务，KORU Medical在药物开发过程中为生物制药公司提供用于可行性/临床试验的产品，并根据需要定制Freedom系统，用于多种药物类别的临床和商业用途。

For more information, please visit www.korumedical.com..

有关更多信息，请访问www.korumedical.com。。